ABSTRACT
INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are digestive tract sarcomas originating from the interstitial cells of Cajal [1] . Most GISTs develop in the stomach and small intestine and frequently metastasize to the liver and peritoneum. Lymph node and lung metastases are rare [2] .
Activating mutations of the KIT oncogene are the pathogenic hallmark of GISTs and are present in 75-85% of tumors [1] [2] [3] .
Approximately 65% of KIT mutations involve the juxtamembrane domain of the KIT receptor encoded by exon 11, and 7-10% involve exon 9, which encodes the extracellular domain [3] .
Ten percent of GISTs harbor mutations in the platelet-derived growth factor receptor alpha (PDGFRA) gene, which occur mutually exclusive of KIT mutations, and another 10-15% are KIT/ PDGFRA wild-type [3] . Up to 50% of these previously termed wild-type GISTs demonstrate defects in succinate dehydrogenase (SDH), which is associated with pediatric GISTs [4] . Mutations in PIK3CA and NF1 (neurofibromatosis type 1) have also been identified very infrequently [3] .
The connection between KIT mutations and In the 15 years that have since passed, the therapeutic repertory for metastatic GIST has expanded significantly and includes additional targeted agents as well as new locoregional techniques. This review will discuss the current therapeutic landscape for metastatic GISTs.
SYSTEMIC THERAPY FOR METASTATIC GIST

Imatinib
In phase I, II, and III studies, imatinib induced objective responses in 45-55% of patients, 3-5% of whom had a complete response [8] [9] [10] [11] . The median time to response was *3-4 months, though some responses were observed up to 2 years later [11] . Median progression-free survival (PFS) and overall survival (OS) were 18-24 months and 50-60 months, respectively [10] [11] [12] . Clinical outcomes were similar across different doses ranging from 400 mg QD to 400 mg BID.
Tumor genotype influences sensitivity to imatinib. KIT exon 11 mutations are associated with significantly better response and survival outcomes compared to exon 9 mutated and wild-type GISTs [13] [14] [15] [16] . Because high dose imatinib (400 mg BID) has been shown to increase the ORR and PFS in patients with exon 9 mutations [13, 16] , patients with this genotype should be closely monitored for progression and dose-escalated as tolerated [17] .
PDGFRA mutations are associated with variable sensitivity to imatinib with the D842V mutation resistant and other mutations generally sensitive to imatinib [18] .
Secondary progression on imatinib is usually the result of acquired secondary KIT mutations in exons 13, 14, 17, and 18, which hinder drug-receptor interactions [3, 19] . KIT amplification, loss of KIT protein expression, and PDGFRA D842V mutations also confer resistance [3, 19] . PFS appeared superior in patients with KIT exon 11 mutations compared to exon 9 mutations.
The phase III GRID trial randomized patients with imatinib and sunitinib-resistant GIST to regorafenib (160 mg QD for 3 weeks of a 4-week cycle) or placebo [33] . The primary endpoint, median PFS, significantly favored regorafenib (4.8 vs 0.9 months, HR 0.27, p\0.0001). The ORR and stable disease rate with regorafenib were 4.5% and 71%, respectively. There was no difference in median OS (HR 0.77, p = 0.199).
Outcomes were similar in patients with KIT exon 9 and 11 mutations. Toxicities mirrored those reported in the phase II trial and responded to dose reductions. In 2013, regorafenib was FDA-approved for the treatment of metastatic GIST refractory to imatinib and sunitinib.
Nilotinib
Nilotinib is a more potent inhibitor of BCR-Abl than imatinib, and also inhibits KIT 
Binimetinib
The ETV1 transcription factor mediates GIST oncogenesis, maintenance, and survival, and is part of a positive feedback loop with KIT [57] .
Inhibition of MAPK signaling using the MEK inhibitor binimetinib destabilizes KIT and synergizes with imatinib. In a phase Ib study of binimetinib and imatinib, the CBR was 65% and ORR was 41% by Choi criteria [58] . Median PFS was 8 weeks. Two patients had stable disease lasting over a year; one was SDH deficient and the other had a KIT exon 11 mutation.
Grade C 3 fatigue, edema, rash, HFSR, gastrointestinal toxicities, electrolyte disturbances, and increased liver enzymes occurred in 17-28% of patients, and 89% had asymptomatic grade 3/4 elevations of CPK. A phase II trial is ongoing (NCT01991379).
PI3K/Akt/mTOR Inhibitors
mTOR activation is a mechanism of secondary resistance to imatinib and occurs in 70% of PDGFRA-mutated and ''wild-type'' GISTs [59, 60] . Based on preclinical data showing synergy [61] , everolimus was combined with imatinib in several phase II studies [62, 63] . Median PFS and OS were 1.9 and 14.9 months, respectively, in second line, and 3.5 and 10.7 months, respectively, in third-line [61] . Thirty to 40% of patients had stable disease [62, 63] .
Preclinical data suggest suppression of PI3K or Akt may yield greater therapeutic benefit [64] . In a phase II trial, the Akt inhibitor perifosine plus imatinib yielded a CBR of 36% in patients with imatinib-resistant disease, especially those with wild-type tumors. Median PFS and OS were 2.2 and 18.3 months, respectively [65] . Several clinical trials of PI3K inhibitors in GIST are underway (NCT01468688, NCT01735968) [64] .
Heat Shock Protein 90 Inhibitors
Heat shock protein 90 (HSP90) is a chaperone molecule that protects protein integrity, including mediators of oncogenesis, growth, and maintenance [66] . Preclinical studies have shown that the antineoplastic effects of HSP90 inhibition in GIST cell lines are mediated by KIT degradation [67] .
The HSP90 inhibitor retaspimycin has been evaluated in several clinical trials. In a phase I study, ORR was 3% by RECIST and 38% on PET [68] . Median PFS and TTP were 10.6 and 12 weeks, respectively. One patient with imatinib and sunitinib-resistant disease remained on retaspimycin for 5 years. The most common toxicities were fatigue, nausea, headache, diarrhea, and vomiting. Grade 1-2 arrhythmias and QTc prolongation occurred in 2-20% of patients. A phase III study of retaspimycin versus placebo in TKI-resistant GIST was terminated early due to four drug-related deaths [69] .
Other HSP90 inhibitors such as BIIB021, AT13387, and ganetespib have shown good tolerability and disease-stabilizing activity in GISTs [70] [71] [72] .
Immunotherapy
The GIST microenvironment contains regulatory, cytotoxic, proinflammatory, and anti-inflammatory cells, which appear to create a net immunosuppressive effect [73, 74] .
GIST infiltrating lymphocytes demonstrate upregulation of the programmed-death receptor-1 (PD-1) and ligand (PD-L1), which dampen immune responses [75] . Imatinib increases the ratio of cytotoxic to regulatory T cells and enhances cross-talk between dendritic and natural killer cells [76, 77] , providing a rationale for evaluating immunotherapy combined with TKIs in metastatic GIST.
In a phase Ib trial of dasatinib and the anti-CTLA4 inhibitor ipilimumab, four out of eight GIST patients had durable disease control [78] . PD-1/PD-L1 axis inhibition demonstrated an additive antiproliferative effect on murine GISTs when combined with imatinib [75] . In a cohort of eight patients, imatinib and pegylated interferon-alpha 2b yielded an ORR of 100% and OS was 100% after a median follow-up of 3.6 years [79] .
A summary of these agents and their associated outcomes is provided in Table 1 .
LOCOREGIONAL THERAPY FOR METASTATIC DISEASE
Although TKIs are the therapeutic mainstay for metastatic GIST, locoregional approaches can Selected patients with limited progression, gastric GISTs, smaller tumor size and number, and completely cytoreducible disease may also benefit from surgery [84] . Those with generalized disease do not benefit from cytoreduction [82, 83] . Imatinib should be resumed post-operatively to reduce the risk of recurrence or progression.
Radiotherapy (RT)
Though long considered radioresistant, GIST metastases can be effectively palliated by RT [85] [86] [87] . In a prospective study of 25 patients with TKI-refractory GIST, 80% had stability of target lesions lasting a median of 16 months and median OS was 19 months [87] . Median TTP of target lesions was significantly longer in patients who did not continue TKIs during RT than in those who did (23 vs 11 months, p = 0.014). One patient developed grade 4 biliary tract necrosis while taking sorafenib during RT.
Hepatic Artery Embolization (HAE)
HAE involves the selective catheterization and delivery of microspheres through a tumor-feeding artery, inducing ischemia and apoptosis. Transarterial chemoembolization (TACE) is HAE performed with chemotherapy. Response rates using modified RECIST guidelines, which only measure arterially enhancing disease instead of the entire tumor diameter, are 45-54% [88, 89] . Median liver PFS and OS times range from 3.4 to 8.2 months and 9.7-23.8 months, respectively. The absence of extrahepatic metastases, multiple versus single embolizations, fewer liver metastases, and disease control following embolizations are independently associated with improved survival on multivariate analyses [88, 90, 91] .
The main side effect of HAE/TACE is post-embolization syndrome consisting of abdominal pain, fatigue, fever, nausea and vomiting. Moderate to severe complications including liver failure, abscess, respiratory failure, pulmonary embolism, cholecystitis and hemorrhage occur in 5-14% of patients [88, 90, 91] . When used, the authors recommend bland HAE rather than TACE given the lack of sensitivity to standard chemotherapy agents, even at very high concentrations.
Radiofrequency Ablation (RFA)
RFA induces coagulative necrosis of tumors using thermal energy.
In small retrospective series, complete ablation was achieved in [90% of treated tumors, and 3-and 5-year local tumor progression rates were 0% and 12.5%, respectively [92] [93] [94] . As with cytoreductive surgery, patients who undergo RFA for residual disease after maximal response to imatinib experienced the best outcomes [92] .
Radioembolization
Radioembolization with yttrium-90 selectively delivers high dose radiation to target lesions while sparing the normal hepatic parenchyma.
In a small retrospective series of nine evaluable patients with progressive GIST on C2 prior TKIs, 33% had a complete response, 56% had a partial response and 11% had stable disease [95] .
Median hepatic PFS was 16 months and OS was nearly 30 months. Toxicities primarily consisted of increased liver enzymes which were mostly grade 1, although one patient developed a chronic gastric ulcer and required surgery.
Outcomes associated with various locoregional therapies are summarized in Table 2 . Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.
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